Sotera Health (NASDAQ:SHC – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.950-1.010 for the period, compared to the consensus EPS estimate of 0.950. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.
Analysts Set New Price Targets
A number of analysts have issued reports on SHC shares. Barclays boosted their price target on shares of Sotera Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. UBS Group set a $19.00 price objective on shares of Sotera Health in a report on Wednesday, June 24th. Weiss Ratings raised shares of Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 9th. Piper Sandler reiterated an “overweight” rating and set a $22.00 target price (down from $24.00) on shares of Sotera Health in a report on Wednesday, May 6th. Finally, The Goldman Sachs Group started coverage on shares of Sotera Health in a research report on Friday, June 5th. They issued a “buy” rating and a $20.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Sotera Health has a consensus rating of “Moderate Buy” and a consensus target price of $20.25.
Check Out Our Latest Report on SHC
Sotera Health Stock Up 5.2%
Sotera Health (NASDAQ:SHC – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The company had revenue of $321.38 million during the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a net margin of 9.91% and a return on equity of 39.73%. The firm’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 earnings per share. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. As a group, equities analysts forecast that Sotera Health will post 0.87 EPS for the current year.
Insider Buying and Selling
In other Sotera Health news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total transaction of $193,194,516.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 15.36% of the stock is currently owned by corporate insiders.
Trending Headlines about Sotera Health
Here are the key news stories impacting Sotera Health this week:
- Positive Sentiment: Quarterly earnings and revenue exceeded expectations. Adjusted EPS was $0.26 versus the $0.24 consensus estimate, while revenue increased 9.2% year over year to $321.4 million, above estimates of $309.7 million. Adjusted EBITDA rose 10% and the margin expanded to 51.6%. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
- Positive Sentiment: Management raised its 2026 outlook. The company now expects constant-currency revenue growth of 5.25% to 6.75%, Adjusted EBITDA growth of 5.75% to 7.25% and Adjusted EPS of $0.95 to $1.01. The EPS range is above the prior outlook and compares with a $0.95 analyst consensus at the low end. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
- Positive Sentiment: Growth was diversified across business units. Sterigenics revenue grew 7.0% on a constant-currency basis, Nordion increased 16.7%, and Nelson Labs rose 5.4%. Net income climbed to $53.6 million from $8.0 million a year earlier, while operating cash flow for the first half reached $117.9 million.
- Positive Sentiment: Balance-sheet trends improved. SHC repriced its term loan, expected to save approximately $3.5 million in annual interest expense. Net leverage improved to 3.0x from 3.2x, reaching the company’s target range, with approximately $950 million of available liquidity. Sotera Health Q2 2026 Earnings Call Transcript
- Neutral Sentiment: Investors should note that the outlook depends on continued access to ethylene oxide and Cobalt-60, stable supply chains and manageable inflation. Total debt remained substantial at roughly $2.2 billion.
- Negative Sentiment: Ethylene oxide-related litigation, regulatory exposure and related professional costs remain ongoing risks, while higher costs pressured Nelson Labs’ year-to-date segment income.
Institutional Trading of Sotera Health
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Empowered Funds LLC lifted its position in Sotera Health by 11.1% in the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after purchasing an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Sotera Health by 14.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after purchasing an additional 43,471 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after purchasing an additional 14,018 shares during the last quarter. Creative Planning raised its position in shares of Sotera Health by 15.3% in the second quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after buying an additional 2,673 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Sotera Health by 4.2% during the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock worth $3,549,000 after purchasing an additional 12,758 shares during the period. Hedge funds and other institutional investors own 91.03% of the company’s stock.
About Sotera Health
Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.
Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.
Read More
- Five stocks we like better than Sotera Health
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
